nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—MAOA—Parkinson's disease	0.28	0.361	CbGaD
Phenylpropanolamine—DRD1—Parkinson's disease	0.255	0.328	CbGaD
Phenylpropanolamine—SLC6A3—Parkinson's disease	0.242	0.311	CbGaD
Phenylpropanolamine—SLC6A2—locus ceruleus—Parkinson's disease	0.00595	0.0833	CbGeAlD
Phenylpropanolamine—MAOA—locus ceruleus—Parkinson's disease	0.00548	0.0767	CbGeAlD
Phenylpropanolamine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.0047	0.0658	CbGeAlD
Phenylpropanolamine—DRD1—telencephalic ventricle—Parkinson's disease	0.00435	0.0609	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00349	0.049	CbGeAlD
Phenylpropanolamine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00316	0.0443	CbGeAlD
Phenylpropanolamine—DRD1—nerve—Parkinson's disease	0.00274	0.0384	CbGeAlD
Phenylpropanolamine—SLC6A3—nerve—Parkinson's disease	0.0022	0.0309	CbGeAlD
Phenylpropanolamine—SLC6A2—nerve—Parkinson's disease	0.00178	0.0249	CbGeAlD
Phenylpropanolamine—SLC6A3—hindbrain—Parkinson's disease	0.00165	0.0231	CbGeAlD
Phenylpropanolamine—MAOA—nerve—Parkinson's disease	0.00164	0.0229	CbGeAlD
Phenylpropanolamine—ADRA2A—peripheral nervous system—Parkinson's disease	0.00161	0.0226	CbGeAlD
Phenylpropanolamine—ADRA1A—hindbrain—Parkinson's disease	0.00124	0.0173	CbGeAlD
Phenylpropanolamine—MAOA—hindbrain—Parkinson's disease	0.00123	0.0172	CbGeAlD
Phenylpropanolamine—DRD1—brainstem—Parkinson's disease	0.00118	0.0165	CbGeAlD
Phenylpropanolamine—DRD1—forebrain—Parkinson's disease	0.00114	0.0159	CbGeAlD
Phenylpropanolamine—SLC6A3—brainstem—Parkinson's disease	0.000945	0.0132	CbGeAlD
Phenylpropanolamine—SLC6A3—forebrain—Parkinson's disease	0.000913	0.0128	CbGeAlD
Phenylpropanolamine—ADRB1—forebrain—Parkinson's disease	0.000866	0.0121	CbGeAlD
Phenylpropanolamine—MAOA—embryo—Parkinson's disease	0.000767	0.0107	CbGeAlD
Phenylpropanolamine—SLC6A2—brainstem—Parkinson's disease	0.000763	0.0107	CbGeAlD
Phenylpropanolamine—DRD1—midbrain—Parkinson's disease	0.00075	0.0105	CbGeAlD
Phenylpropanolamine—SLC6A2—forebrain—Parkinson's disease	0.000736	0.0103	CbGeAlD
Phenylpropanolamine—ADRB1—cardiovascular system—Parkinson's disease	0.000732	0.0103	CbGeAlD
Phenylpropanolamine—ADRA1A—brainstem—Parkinson's disease	0.000709	0.00994	CbGeAlD
Phenylpropanolamine—MAOA—brainstem—Parkinson's disease	0.000703	0.00985	CbGeAlD
Phenylpropanolamine—ADRA1A—forebrain—Parkinson's disease	0.000684	0.00959	CbGeAlD
Phenylpropanolamine—MAOA—forebrain—Parkinson's disease	0.000678	0.0095	CbGeAlD
Phenylpropanolamine—DRD1—head—Parkinson's disease	0.00065	0.00911	CbGeAlD
Phenylpropanolamine—Ephedrine—SLC18A2—Parkinson's disease	0.000649	0.0854	CrCbGaD
Phenylpropanolamine—DRD1—nervous system—Parkinson's disease	0.000616	0.00864	CbGeAlD
Phenylpropanolamine—SLC6A3—midbrain—Parkinson's disease	0.000603	0.00844	CbGeAlD
Phenylpropanolamine—DRD1—central nervous system—Parkinson's disease	0.000593	0.00831	CbGeAlD
Phenylpropanolamine—SLC6A3—spinal cord—Parkinson's disease	0.000588	0.00824	CbGeAlD
Phenylpropanolamine—ADRA1A—cardiovascular system—Parkinson's disease	0.000579	0.00811	CbGeAlD
Phenylpropanolamine—MAOA—cardiovascular system—Parkinson's disease	0.000574	0.00804	CbGeAlD
Phenylpropanolamine—SLC6A2—medulla oblongata—Parkinson's disease	0.000532	0.00745	CbGeAlD
Phenylpropanolamine—SLC6A3—head—Parkinson's disease	0.000522	0.00732	CbGeAlD
Phenylpropanolamine—ADRA2A—forebrain—Parkinson's disease	0.00052	0.00729	CbGeAlD
Phenylpropanolamine—ADRB1—head—Parkinson's disease	0.000496	0.00694	CbGeAlD
Phenylpropanolamine—SLC6A3—nervous system—Parkinson's disease	0.000495	0.00694	CbGeAlD
Phenylpropanolamine—Dextroamphetamine—SLC18A2—Parkinson's disease	0.000495	0.0652	CrCbGaD
Phenylpropanolamine—MAOA—medulla oblongata—Parkinson's disease	0.00049	0.00687	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—Parkinson's disease	0.000477	0.00668	CbGeAlD
Phenylpropanolamine—DRD1—brain—Parkinson's disease	0.000471	0.0066	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—Parkinson's disease	0.00047	0.00658	CbGeAlD
Phenylpropanolamine—L-Phenylalanine—TH—Parkinson's disease	0.000468	0.0615	CrCbGaD
Phenylpropanolamine—SLC6A3—cerebellum—Parkinson's disease	0.000466	0.00653	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—Parkinson's disease	0.000452	0.00634	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—Parkinson's disease	0.000448	0.00628	CbGeAlD
Phenylpropanolamine—MAOA—spinal cord—Parkinson's disease	0.000437	0.00612	CbGeAlD
Phenylpropanolamine—Tranylcypromine—MAOB—Parkinson's disease	0.000425	0.0559	CrCbGaD
Phenylpropanolamine—SLC6A2—head—Parkinson's disease	0.000422	0.00591	CbGeAlD
Phenylpropanolamine—SLC6A2—nervous system—Parkinson's disease	0.0004	0.0056	CbGeAlD
Phenylpropanolamine—Amphetamine—SLC18A2—Parkinson's disease	0.000399	0.0525	CrCbGaD
Phenylpropanolamine—ADRA1A—head—Parkinson's disease	0.000392	0.00549	CbGeAlD
Phenylpropanolamine—MAOA—head—Parkinson's disease	0.000388	0.00544	CbGeAlD
Phenylpropanolamine—SLC6A2—central nervous system—Parkinson's disease	0.000385	0.00539	CbGeAlD
Phenylpropanolamine—SLC6A3—brain—Parkinson's disease	0.000379	0.00531	CbGeAlD
Phenylpropanolamine—ADRA2A—medulla oblongata—Parkinson's disease	0.000376	0.00527	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—Parkinson's disease	0.000372	0.00521	CbGeAlD
Phenylpropanolamine—Methamphetamine—SLC18A2—Parkinson's disease	0.00037	0.0487	CrCbGaD
Phenylpropanolamine—MAOA—nervous system—Parkinson's disease	0.000368	0.00516	CbGeAlD
Phenylpropanolamine—ADRB1—brain—Parkinson's disease	0.000359	0.00503	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—Parkinson's disease	0.000358	0.00501	CbGeAlD
Phenylpropanolamine—Phentermine—MAOB—Parkinson's disease	0.000356	0.0469	CrCbGaD
Phenylpropanolamine—MAOA—central nervous system—Parkinson's disease	0.000355	0.00497	CbGeAlD
Phenylpropanolamine—ADRA1A—cerebellum—Parkinson's disease	0.00035	0.0049	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—Parkinson's disease	0.000346	0.00485	CbGeAlD
Phenylpropanolamine—ADRA2A—midbrain—Parkinson's disease	0.000344	0.00481	CbGeAlD
Phenylpropanolamine—ADRA2A—spinal cord—Parkinson's disease	0.000335	0.0047	CbGeAlD
Phenylpropanolamine—SLC6A2—brain—Parkinson's disease	0.000305	0.00428	CbGeAlD
Phenylpropanolamine—Tranylcypromine—MAOA—Parkinson's disease	0.000298	0.0392	CrCbGaD
Phenylpropanolamine—ADRA2A—head—Parkinson's disease	0.000298	0.00417	CbGeAlD
Phenylpropanolamine—Phenelzine—MAOB—Parkinson's disease	0.00029	0.0382	CrCbGaD
Phenylpropanolamine—ADRA1A—brain—Parkinson's disease	0.000284	0.00398	CbGeAlD
Phenylpropanolamine—ADRA2A—nervous system—Parkinson's disease	0.000282	0.00396	CbGeAlD
Phenylpropanolamine—MAOA—brain—Parkinson's disease	0.000281	0.00394	CbGeAlD
Phenylpropanolamine—Amphetamine—MAOB—Parkinson's disease	0.000274	0.036	CrCbGaD
Phenylpropanolamine—ADRA2A—central nervous system—Parkinson's disease	0.000272	0.00381	CbGeAlD
Phenylpropanolamine—ADRA2A—cerebellum—Parkinson's disease	0.000266	0.00372	CbGeAlD
Phenylpropanolamine—Methamphetamine—MAOB—Parkinson's disease	0.000254	0.0334	CrCbGaD
Phenylpropanolamine—Phentermine—MAOA—Parkinson's disease	0.00025	0.0329	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—MAOA—Parkinson's disease	0.000237	0.0311	CrCbGaD
Phenylpropanolamine—ADRA2A—brain—Parkinson's disease	0.000216	0.00303	CbGeAlD
Phenylpropanolamine—Phentermine—SLC6A3—Parkinson's disease	0.000215	0.0283	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—SLC6A3—Parkinson's disease	0.000205	0.027	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A3—Parkinson's disease	0.000204	0.0269	CrCbGaD
Phenylpropanolamine—Phenelzine—MAOA—Parkinson's disease	0.000204	0.0268	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—TNF—Parkinson's disease	0.00019	0.025	CrCbGaD
Phenylpropanolamine—Tranylcypromine—CYP2E1—Parkinson's disease	0.000184	0.0242	CrCbGaD
Phenylpropanolamine—Methamphetamine—MAOA—Parkinson's disease	0.000178	0.0234	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A3—Parkinson's disease	0.000166	0.0218	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A3—Parkinson's disease	0.000153	0.0202	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP2E1—Parkinson's disease	0.000149	0.0196	CrCbGaD
Phenylpropanolamine—Tranylcypromine—CYP2D6—Parkinson's disease	0.000135	0.0178	CrCbGaD
Phenylpropanolamine—Phenelzine—CYP2E1—Parkinson's disease	0.000126	0.0165	CrCbGaD
Phenylpropanolamine—Amphetamine—DRD2—Parkinson's disease	0.000123	0.0162	CrCbGaD
Phenylpropanolamine—Phentermine—CYP2D6—Parkinson's disease	0.000113	0.0149	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP2D6—Parkinson's disease	0.000109	0.0144	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—CYP2D6—Parkinson's disease	0.000108	0.0142	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—CYP2D6—Parkinson's disease	0.000107	0.0141	CrCbGaD
Phenylpropanolamine—Amphetamine—CYP2D6—Parkinson's disease	8.7e-05	0.0114	CrCbGaD
Phenylpropanolamine—Methamphetamine—CYP2D6—Parkinson's disease	8.06e-05	0.0106	CrCbGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—ADORA2A—Parkinson's disease	2.17e-05	0.000151	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	2.17e-05	0.000151	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PDYN—Parkinson's disease	2.16e-05	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD1—Parkinson's disease	2.16e-05	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—ADRBK1—Parkinson's disease	2.14e-05	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD2—Parkinson's disease	2.12e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR7—Parkinson's disease	2.12e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PDYN—Parkinson's disease	2.11e-05	0.000147	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—IL6—Parkinson's disease	2.09e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD3—Parkinson's disease	2.09e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GRK5—Parkinson's disease	2.09e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—EDN1—Parkinson's disease	2.08e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR1A—Parkinson's disease	2.08e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD2—Parkinson's disease	2.08e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR7—Parkinson's disease	2.08e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—DDC—Parkinson's disease	2.06e-05	0.000143	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—TAC1—Parkinson's disease	2.04e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ND3—Parkinson's disease	2.04e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MCCC1—Parkinson's disease	2.04e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GFAP—Parkinson's disease	2.03e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR1A—Parkinson's disease	2.03e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GRM4—Parkinson's disease	2.02e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GRM5—Parkinson's disease	2.01e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD1—Parkinson's disease	2.01e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TAC1—Parkinson's disease	2e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GFAP—Parkinson's disease	1.99e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GRM5—Parkinson's disease	1.96e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD1—Parkinson's disease	1.96e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FGF20—Parkinson's disease	1.96e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—ADRBK1—Parkinson's disease	1.95e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD3—Parkinson's disease	1.94e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTA4—Parkinson's disease	1.94e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CYP2D6—Parkinson's disease	1.93e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—OMD—Parkinson's disease	1.92e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TALDO1—Parkinson's disease	1.92e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PENK—Parkinson's disease	1.91e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAG—Parkinson's disease	1.91e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ADORA2A—Parkinson's disease	1.9e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD3—Parkinson's disease	1.9e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD2—Parkinson's disease	1.89e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR7—Parkinson's disease	1.89e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CTGF—Parkinson's disease	1.89e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EDN1—Parkinson's disease	1.89e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR1A—Parkinson's disease	1.89e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GRM4—Parkinson's disease	1.87e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—EDN1—Parkinson's disease	1.87e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TAC1—Parkinson's disease	1.86e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—EDN1—Parkinson's disease	1.83e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD1—Parkinson's disease	1.82e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HTR2A—Parkinson's disease	1.82e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NDUFB11—Parkinson's disease	1.82e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—ADRBK1—Parkinson's disease	1.81e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PENK—Parkinson's disease	1.78e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAG—Parkinson's disease	1.78e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—ADRBK1—Parkinson's disease	1.77e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD3—Parkinson's disease	1.76e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CYP2E1—Parkinson's disease	1.76e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGF20—Parkinson's disease	1.76e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD2—Parkinson's disease	1.76e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR7—Parkinson's disease	1.76e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—INSR—Parkinson's disease	1.75e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLA2G6—Parkinson's disease	1.75e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PDYN—Parkinson's disease	1.75e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—NQO1—Parkinson's disease	1.74e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCH1—Parkinson's disease	1.74e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MAOB—Parkinson's disease	1.73e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGF20—Parkinson's disease	1.72e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD2—Parkinson's disease	1.72e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR7—Parkinson's disease	1.72e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TH—Parkinson's disease	1.72e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ADORA2A—Parkinson's disease	1.71e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EDN1—Parkinson's disease	1.7e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADORA2A—Parkinson's disease	1.67e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EDN1—Parkinson's disease	1.66e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FGB—Parkinson's disease	1.66e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HTR2A—Parkinson's disease	1.65e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR1A—Parkinson's disease	1.65e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CYCS—Parkinson's disease	1.65e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—ADRBK1—Parkinson's disease	1.65e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GFAP—Parkinson's disease	1.64e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HTR2A—Parkinson's disease	1.64e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GRM5—Parkinson's disease	1.62e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PDYN—Parkinson's disease	1.62e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TAC1—Parkinson's disease	1.62e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR2A—Parkinson's disease	1.6e-05	0.000111	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD2—Parkinson's disease	1.6e-05	0.000111	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR7—Parkinson's disease	1.6e-05	0.000111	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—INSR—Parkinson's disease	1.58e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	1.57e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—FBP1—Parkinson's disease	1.55e-05	0.000108	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—DBH—Parkinson's disease	1.55e-05	0.000108	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GBA—Parkinson's disease	1.55e-05	0.000108	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—INSR—Parkinson's disease	1.54e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD3—Parkinson's disease	1.54e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GFAP—Parkinson's disease	1.53e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—EDN1—Parkinson's disease	1.51e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GRM5—Parkinson's disease	1.51e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGB—Parkinson's disease	1.49e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR2A—Parkinson's disease	1.49e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR1A—Parkinson's disease	1.48e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—COMT—Parkinson's disease	1.46e-05	0.000102	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TAC1—Parkinson's disease	1.46e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGB—Parkinson's disease	1.46e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR2A—Parkinson's disease	1.45e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTP1—Parkinson's disease	1.45e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR1A—Parkinson's disease	1.45e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.44e-05	0.0001	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ADRBK1—Parkinson's disease	1.44e-05	0.0001	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—HMOX1—Parkinson's disease	1.43e-05	9.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD1—Parkinson's disease	1.43e-05	9.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TAC1—Parkinson's disease	1.43e-05	9.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGF20—Parkinson's disease	1.42e-05	9.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—EDN1—Parkinson's disease	1.41e-05	9.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD1—Parkinson's disease	1.4e-05	9.74e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR7—Parkinson's disease	1.39e-05	9.7e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD2—Parkinson's disease	1.39e-05	9.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD3—Parkinson's disease	1.39e-05	9.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADORA2A—Parkinson's disease	1.38e-05	9.61e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ABCB1—Parkinson's disease	1.37e-05	9.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EDN1—Parkinson's disease	1.37e-05	9.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD3—Parkinson's disease	1.36e-05	9.43e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTM1—Parkinson's disease	1.33e-05	9.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR2A—Parkinson's disease	1.32e-05	9.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGF20—Parkinson's disease	1.32e-05	9.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ADRBK1—Parkinson's disease	1.29e-05	9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP2D6—Parkinson's disease	1.29e-05	8.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADORA2A—Parkinson's disease	1.28e-05	8.93e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GPX1—Parkinson's disease	1.28e-05	8.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EDN1—Parkinson's disease	1.28e-05	8.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INSR—Parkinson's disease	1.28e-05	8.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADRBK1—Parkinson's disease	1.27e-05	8.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CTGF—Parkinson's disease	1.26e-05	8.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR7—Parkinson's disease	1.25e-05	8.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD2—Parkinson's disease	1.25e-05	8.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR2A—Parkinson's disease	1.23e-05	8.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD2—Parkinson's disease	1.23e-05	8.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR7—Parkinson's disease	1.23e-05	8.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGB—Parkinson's disease	1.21e-05	8.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR2A—Parkinson's disease	1.2e-05	8.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR1A—Parkinson's disease	1.2e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INSR—Parkinson's disease	1.18e-05	8.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TAC1—Parkinson's disease	1.18e-05	8.21e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—MTHFR—Parkinson's disease	1.18e-05	8.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP2E1—Parkinson's disease	1.18e-05	8.18e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF2—Parkinson's disease	1.17e-05	8.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NQO1—Parkinson's disease	1.16e-05	8.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD1—Parkinson's disease	1.16e-05	8.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TH—Parkinson's disease	1.15e-05	7.98e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—DDC—Parkinson's disease	1.14e-05	7.9e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1R—Parkinson's disease	1.13e-05	7.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD3—Parkinson's disease	1.12e-05	7.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGB—Parkinson's disease	1.12e-05	7.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—Parkinson's disease	1.12e-05	7.77e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EDN1—Parkinson's disease	1.12e-05	7.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR1A—Parkinson's disease	1.11e-05	7.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYCS—Parkinson's disease	1.1e-05	7.66e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOE—Parkinson's disease	1.1e-05	7.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TAC1—Parkinson's disease	1.1e-05	7.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD1—Parkinson's disease	1.08e-05	7.48e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTA4—Parkinson's disease	1.07e-05	7.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.06e-05	7.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF2—Parkinson's disease	1.05e-05	7.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADRBK1—Parkinson's disease	1.05e-05	7.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD3—Parkinson's disease	1.04e-05	7.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF2—Parkinson's disease	1.03e-05	7.15e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NGF—Parkinson's disease	1.03e-05	7.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1R—Parkinson's disease	1.02e-05	7.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD2—Parkinson's disease	1.01e-05	7.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR7—Parkinson's disease	1.01e-05	7.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EDN1—Parkinson's disease	1e-05	6.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1R—Parkinson's disease	9.93e-06	6.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EDN1—Parkinson's disease	9.82e-06	6.83e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—Parkinson's disease	9.76e-06	6.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—COMT—Parkinson's disease	9.75e-06	6.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	9.73e-06	6.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTP1—Parkinson's disease	9.7e-06	6.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MAOA—Parkinson's disease	9.68e-06	6.73e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	9.65e-06	6.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HMOX1—Parkinson's disease	9.57e-06	6.66e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MAOB—Parkinson's disease	9.56e-06	6.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	9.42e-06	6.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	9.42e-06	6.55e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—INS—Parkinson's disease	9.38e-06	6.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NGF—Parkinson's disease	9.22e-06	6.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ABCB1—Parkinson's disease	9.19e-06	6.39e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	9.09e-06	6.33e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—Parkinson's disease	9.08e-06	6.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NGF—Parkinson's disease	9.02e-06	6.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTM1—Parkinson's disease	8.92e-06	6.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—Parkinson's disease	8.78e-06	6.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—Parkinson's disease	8.59e-06	5.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GPX1—Parkinson's disease	8.54e-06	5.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF2—Parkinson's disease	8.5e-06	5.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1R—Parkinson's disease	8.22e-06	5.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—Parkinson's disease	8.16e-06	5.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EDN1—Parkinson's disease	8.12e-06	5.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—Parkinson's disease	7.98e-06	5.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	7.9e-06	5.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MTHFR—Parkinson's disease	7.88e-06	5.48e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—INS—Parkinson's disease	7.76e-06	5.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	7.63e-06	5.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	7.54e-06	5.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NGF—Parkinson's disease	7.46e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—Parkinson's disease	7.34e-06	5.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—Parkinson's disease	7.1e-06	4.94e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	7.1e-06	4.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—INS—Parkinson's disease	6.97e-06	4.85e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CTGF—Parkinson's disease	6.97e-06	4.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	6.93e-06	4.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—INS—Parkinson's disease	6.82e-06	4.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—Parkinson's disease	6.6e-06	4.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	6.6e-06	4.59e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	6.5e-06	4.52e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NQO1—Parkinson's disease	6.42e-06	4.47e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TH—Parkinson's disease	6.33e-06	4.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—INS—Parkinson's disease	6.27e-06	4.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	6.14e-06	4.27e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYCS—Parkinson's disease	6.08e-06	4.23e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—Parkinson's disease	5.77e-06	4.02e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—Parkinson's disease	5.74e-06	3.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INS—Parkinson's disease	5.64e-06	3.92e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—Parkinson's disease	5.38e-06	3.74e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—Parkinson's disease	5.36e-06	3.73e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MAOA—Parkinson's disease	5.34e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK8—Parkinson's disease	5.31e-06	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—Parkinson's disease	5.28e-06	3.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INS—Parkinson's disease	5.24e-06	3.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—Parkinson's disease	5.19e-06	3.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—Parkinson's disease	5.16e-06	3.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—Parkinson's disease	5.08e-06	3.53e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—Parkinson's disease	5.07e-06	3.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—Parkinson's disease	5.04e-06	3.51e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—Parkinson's disease	4.92e-06	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK8—Parkinson's disease	4.77e-06	3.32e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—Parkinson's disease	4.71e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK8—Parkinson's disease	4.67e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—Parkinson's disease	4.35e-06	3.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—Parkinson's disease	4.2e-06	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—Parkinson's disease	4.17e-06	2.9e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—Parkinson's disease	4.05e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	3.9e-06	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	3.88e-06	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK8—Parkinson's disease	3.86e-06	2.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	3.59e-06	2.49e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INS—Parkinson's disease	3.46e-06	2.41e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—Parkinson's disease	3.39e-06	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—Parkinson's disease	3.05e-06	2.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—Parkinson's disease	2.98e-06	2.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—Parkinson's disease	2.46e-06	1.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	2.29e-06	1.59e-05	CbGpPWpGaD
